Related Experiment Video
Updated: Jun 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Therapy of dyslipidemia in rheumatic diseases]
S Vordenbäumen1, S Schinner, M Halle
1Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Deutschland. stefan.vordenbaeumen@med.uni-duesseldorf.de
Insights
Patients with rheumatic diseases face higher cardiovascular risks due to dyslipidemia. Statins are recommended for managing lipid profiles and reducing mortality in these patients.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Abstract:
Cardiovascular diseases are the main cause of death worldwide and dyslipidemia constitutes a substantial risk factor. Patients with rheumatic diseases, especially active inflammatory arthritis and systemic lupus erythematosus, show unfavorable lipid profiles, which, however, do not account for the total excess cardiovascular morbidity. Effective disease management, life-style changes and cholesterol-lowering agents can ameliorate the lipid profile and lower cardiovascular mortality. Due to their anti-inflammatory and potent cholesterol-lowering properties, statins are the pharmacological agents of first choice. National and international guidelines on cardiovascular risk prevention differ concerning appraisal of the individual risk and lipid targets. The EULAR recently released recommendations for cardiovascular risk management in patients with inflammatory arthritis.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction